CAR-T therapy may be an option for selected patients with leukemia that has returned after treatment or has not responded adequately to standard therapy.
It is most established for B-cell acute lymphoblastic leukemia (B-cell ALL) and may also be considered for selected patients with chronic lymphocytic leukemia (CLL). The appropriate treatment pathway depends on the exact leukemia type, previous treatments, current disease status and the patient’s overall condition.
Request a free CAR-T eligibility check >>

Which leukemia types may be treated with CAR-T?
CAR-T is not one treatment for every type of leukemia. It is most commonly considered for patients with B-cell cancers that express a suitable target on the leukemia cells.
B-cell acute lymphoblastic leukemia (ALL)
CAR-T is an established treatment option for selected children, young adults and adults with B-cell ALL that has relapsed or has not responded to treatment. It may be considered when leukemia returns after a bone marrow transplant, does not respond to first-line therapy, or returns after several previous treatments.
Chronic lymphocytic leukemia (CLL)
CAR-T may also be considered for selected adults with CLL whose disease has progressed after several previous treatments. Suitability depends on the treatment history, the current condition of the disease, blood counts, organ function and whether the patient can safely proceed through the CAR-T process.
Other leukemia types
For acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia and other leukemia types, CAR-T is not currently a standard treatment in most settings. In some cases, it may be available through a specific hospital protocol or clinical study. Every case requires individual medical review.
When should a patient request a CAR-T review?
An early review may be helpful when leukemia has relapsed, has not responded adequately to treatment, or when the treating doctor believes that CAR-T may become relevant soon. A review does not mean that the patient must travel or start treatment. It can help the patient and family understand whether CAR-T may be an option and what information or preparation may be needed.
Time can be important. Some patients need treatment to control the leukemia while CAR-T is being prepared, and the hospital team must decide whether this is medically appropriate.
Celebrating a successful CAR-T therapy with coffee in Tel Aviv in 2019. Updated in 2026: still in remission.
CAR-T evaluation for international patients in Israel
We coordinate the submission of medical records for review by experienced CAR-T teams at leading Israeli hospitals. The hospital determines whether CAR-T may be suitable, which treatment pathway is appropriate and whether additional tests or a remote consultation are required.
International patients are usually asked to provide:
- A copy of the patient’s passport
- A medical summary in English, including the diagnosis and treatment history from diagnosis until today
- Recent blood tests
Request an individual CAR-T eligibility review
Every application is reviewed individually. Submission of medical records does not guarantee eligibility, hospital acceptance, treatment availability or a particular outcome.
Request a free CAR-T eligibility check >>
Updated: November 2026
Sources
National Cancer Institute: CAR T Cells
National Cancer Institute: Adult Acute Lymphoblastic Leukemia Treatment
National Cancer Institute: Childhood Acute Lymphoblastic Leukemia Treatment

